GLP-1s and Heart Health: Can Ozempic, Wegovy, and Zepbound Really Cut Heart Attack and Stroke Risk?

Quick Answer:

Yes, GLP-1 medications like Ozempic, Wegovy, and Zepbound have been proven to significantly reduce the risk of heart attacks, strokes, and cardiovascular death. The landmark SELECT trial showed that semaglutide (Wegovy) reduced major cardiovascular events by 20% in people with obesity and heart disease. Even more impressive? These heart-protective benefits start appearing within just 3-6 months of treatment and work through mechanisms beyond just weight loss.

If you want to get started with GLP-1s right away, SkinnyRx offers several affordable compounded options that can be accessed through a telehealth provider:

See if SkinnyRx is right for you!

GLP-1 medications have exploded in popularity for weight loss, but their cardiovascular benefits might be even more groundbreaking than their ability to help you drop pounds.

If you’ve been following the Ozempic and Wegovy craze, you’ve probably heard about dramatic weight loss results. But here’s what’s flying under the radar: these medications are fundamentally changing how doctors think about preventing heart attacks and strokes.

The data is so compelling that in 2024, the FDA approved Wegovy specifically to reduce cardiovascular risk in people with heart disease, making it the first weight-loss drug ever granted this indication.

So what’s really going on here? Can a weekly injection actually protect your heart? And if so, how does it work?

What the Research Actually Shows
The Landmark SELECT Trial: Game-Changing Results
How GLP-1s Protect Your Heart (Beyond Weight Loss)
Ozempic vs Wegovy vs Zepbound: Cardiovascular Benefits Compared
Who Benefits Most from GLP-1s for Heart Health
How Fast Do the Heart Benefits Start?
The Stroke Connection: Impressive Risk Reductions
Real-World Evidence: What Patients Are Experiencing
Should You Consider GLP-1s for Heart Health?
How to Access GLP-1s for Cardiovascular Protection
Frequently Asked Questions
Key Takeaways
Your Next Steps

What the Research Actually Shows

Over the past several years, multiple large cardiovascular outcome trials have tested GLP-1 medications in thousands of patients with heart disease and diabetes. The results have been consistently impressive.

A meta-analysis pooling data from over 60,000 patients found that GLP-1 receptor agonists reduced:

Major adverse cardiovascular events (MACE) by 14%
All-cause mortality by 12%
Stroke risk by 17%
Heart attacks by varying degrees depending on the specific medication

But here’s what makes the research truly revolutionary: the strongest benefits were seen with semaglutide (the active ingredient in Ozempic and Wegovy), which showed a 26% reduction in major cardiovascular events.

Even more recent studies have shown that oral semaglutide reduced cardiovascular events by 14% in people with type 2 diabetes and existing heart disease.

Infographic showing GLP-1 drugs lowering MACE, mortality, stroke, and highlighting semaglutide heart benefits

The Landmark SELECT Trial: Game-Changing Results

The SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity) trial is arguably the most important cardiovascular study ever conducted on a weight-loss medication.

Here’s why it matters:

Previous GLP-1 studies focused on people with diabetes. SELECT was different—it studied people with obesity or overweight who had existing cardiovascular disease but no diabetes. This proved that the heart benefits weren’t just about controlling blood sugar.

The Results:

Over 17,600 participants were randomized to receive either Wegovy (semaglutide 2.4 mg) or placebo for an average of 40 months (over 3 years).

The primary outcome—major adverse cardiovascular events including cardiovascular death, nonfatal heart attack, and nonfatal stroke—occurred in:

6.5% of people taking Wegovy
8.0% of people taking placebo

That translates to a 20% reduction in risk.

Breaking it down further, a 2025 sub-analysis showed that semaglutide:

Reduced total cardiovascular events by 22%
Reduced nonfatal heart attacks by 31%
Reduced coronary revascularizations (procedures like stents and bypasses) by 26%

What makes this even more impressive? These patients were already on standard heart medications like statins, blood pressure drugs, and antiplatelet therapy. Adding semaglutide on top of those proven treatments provided an additional 10-20% risk reduction.

select trial semaglutide cardiovascular outcomes diagramDiagram summarizing SELECT trial showing semaglutide reducing major cardiovascular events versus placebo in people with obesity and heart disease

How GLP-1s Protect Your Heart (Beyond Weight Loss)

Here’s where it gets really interesting. While weight loss certainly helps your heart, researchers have discovered that GLP-1 medications provide cardiovascular protection through multiple independent mechanisms.

The cardiovascular benefits happen through:

1. Direct Anti-Inflammatory Effects
GLP-1 receptors are found throughout the cardiovascular system. When activated, they reduce inflammation in blood vessels and stabilize atherosclerotic plaques, making them less likely to rupture and cause heart attacks.

2. Improved Endothelial Function
These medications improve the function of the inner lining of blood vessels (the endothelium), which helps regulate blood pressure and prevents clot formation.

3. Blood Pressure Reduction
GLP-1s consistently lower systolic blood pressure by 3-5 mmHg, which contributes to reduced cardiovascular risk.

4. Metabolic Improvements
Better insulin sensitivity, improved lipid profiles, and reduced liver fat all contribute to heart health.

5. Reduced Oxidative Stress
GLP-1 medications decrease harmful oxidative stress in the cardiovascular system.

6. Slowing Atherosclerosis Progression
Studies suggest these medications slow the buildup and progression of arterial plaque.

The key takeaway? Even if you don’t lose a significant amount of weight, you may still get cardiovascular protection from GLP-1 medications.

Ozempic vs Wegovy vs Zepbound: Cardiovascular Benefits Compared

All three medications have shown cardiovascular benefits, but the data varies:

Semaglutide (Ozempic/Wegovy):

SUSTAIN-6 trial: 26% reduction in MACE, primarily driven by 39% reduction in stroke
SELECT trial: 20% reduction in MACE in people without diabetes
FDA approved for cardiovascular risk reduction in people with obesity and heart disease
Benefits seen with both injectable and oral formulations

Tirzepatide (Zepbound/Mounjaro):

Real-world studies: Comparable cardiovascular benefits to semaglutide
Some studies suggest tirzepatide may have slightly better outcomes for heart failure hospitalization
One comparison found tirzepatide had lower risks of myocardial infarction and heart failure events than semaglutide
Major outcomes trial (SUMMIT) showed improvements in heart failure with preserved ejection fraction

Head-to-Head:
A large real-world comparison found that tirzepatide and semaglutide showed comparable cardiovascular benefit, with a hazard ratio of 1.06 (essentially equivalent).

Bottom Line:
Both medications provide significant cardiovascular protection. Semaglutide has more published clinical trial data and FDA approval specifically for cardiovascular risk reduction, while tirzepatide shows promising comparable benefits in real-world studies.

Who Benefits Most from GLP-1s for Heart Health

Based on the clinical trials and real-world evidence, GLP-1 medications provide the most cardiovascular benefit for:

Primary Candidates:

People with obesity or overweight (BMI ≥27) AND existing cardiovascular disease
Those with type 2 diabetes and high cardiovascular risk
Patients who’ve previously had a heart attack or stroke
People with peripheral artery disease
Those with multiple cardiovascular risk factors (high blood pressure, high cholesterol, smoking history)

Emerging Evidence For:

Heart failure with preserved ejection fraction (HFpEF)
Chronic kidney disease with cardiovascular risk
People with obesity without diabetes but with cardiovascular disease

Important Note:
Research shows the cardiovascular benefits are most pronounced in people with BMI ≥25. For those with lower BMIs, the kidney benefits remain consistent, but cardiovascular risk reduction may be less significant.

How Fast Do the Heart Benefits Start?

You don’t have to wait years to see cardiovascular protection. A 2025 analysis of the SELECT trial found remarkably early benefits:

Within 3 months: 38% reduced risk of major cardiovascular events compared to placebo
Within 6 months: 41% reduced risk of major cardiovascular events

This means that within just a few months of starting treatment, people were experiencing significantly fewer heart attacks and strokes.

The benefits continued to increase over time, with the treatment curves separating further at 1.5 years and remaining divergent throughout the study.

The Stroke Connection: Impressive Risk Reductions

One of the most compelling findings in GLP-1 cardiovascular research is the dramatic reduction in stroke risk.

The Data on Strokes:

Ozempic reduced stroke rate by 39% in people with type 2 diabetes and heart disease
A meta-analysis found GLP-1 medications reduced stroke risk by 17% overall
Semaglutide particularly prevented small-vessel occlusion strokes
The stroke benefit appeared regardless of whether patients had a prior stroke at baseline

Why This Matters:

Stroke is the fifth leading cause of death in the United States and a major cause of long-term disability. A medication that can reduce stroke risk by nearly 40% while also helping with weight management represents a significant advancement in preventive cardiology.

Real-World Evidence: What Patients Are Experiencing

Clinical trials are controlled environments. What happens when these medications are used in everyday practice?

Real-world studies have confirmed the cardiovascular benefits extend beyond trial settings:

Large database studies show consistent reductions in heart attacks and strokes
Patients on GLP-1s have lower rates of cardiovascular hospitalizations
The benefits appear across different age groups and genders
Even patients with Type 1 diabetes (an off-label use) showed lower cardiovascular risk when using GLP-1s

Patient Experiences:

Many patients report not just weight loss, but improvements in blood pressure, blood sugar control, and overall energy levels—all factors that contribute to cardiovascular health.

Should You Consider GLP-1s for Heart Health?

The American College of Cardiology released guidelines in 2025 recommending that providers consider GLP-1s as a first-line treatment option for weight management in patients with obesity to reduce cardiovascular risk.

You might be a good candidate if you:

✓ Have obesity or overweight (BMI ≥27) with cardiovascular disease
✓ Have had a previous heart attack, stroke, or cardiovascular event
✓ Have type 2 diabetes with high cardiovascular risk
✓ Have multiple risk factors despite being on standard heart medications
✓ Have struggled with weight management using lifestyle changes alone

You should discuss with your doctor if:

You have a history of pancreatitis
You have a personal or family history of medullary thyroid cancer
You have severe gastrointestinal disease
You’re pregnant or planning pregnancy

Important Considerations:

GLP-1 medications are not a replacement for other cardiovascular treatments. They work best when combined with:

Heart-healthy diet
Regular physical activity
Blood pressure medications (if needed)
Cholesterol-lowering drugs (if needed)
Smoking cessation

How to Access GLP-1s for Cardiovascular Protection

Getting prescribed GLP-1 medications for cardiovascular health depends on several factors:

Traditional Route:

See your doctor (cardiologist, endocrinologist, or primary care)
Discuss your cardiovascular risk and whether you meet FDA criteria
Navigate insurance coverage (coverage varies; Wegovy has cardiovascular indication, which may help)
Pay out-of-pocket if not covered (brand-name versions can cost $900-1,300/month)

Telehealth Compounded Options:

If brand-name medications are too expensive or not covered by insurance, several telehealth providers offer compounded semaglutide and tirzepatide:

SkinnyRx

Compounded semaglutide: Starting at $199/month
Compounded tirzepatide: Starting at $299/month
Includes doctor consultation and ongoing support
Medication shipped directly to you

Check Out SkinnyRx Here

MEDVi

Comprehensive cardiovascular-focused program
Compounded GLP-1 options: $249-$399/month
Includes monitoring and lifestyle coaching
Licensed providers in all 50 states

See if Medvi is right for you!

Enhance.MD

Premium concierge service with nutritionist support
Compounded semaglutide: $299/month
Personalized cardiovascular risk assessment
Regular check-ins with medical team

See if you Qualify for Enhance.MD

Direct Meds

Flexible dosing options
Starting at $179/month for compounded formulations
Easy online consultation process
Fast shipping nationwide

Learn More About Direct Meds Here

Important Note:
Compounded medications are not FDA-approved like brand-name Ozempic, Wegovy, or Zepbound. However, they’re made by licensed U.S. pharmacies using the same active ingredients and prescribed by licensed healthcare providers. They offer a more affordable option for those without insurance coverage.

Frequently Asked Questions

Do GLP-1s prevent heart attacks if you don’t have heart disease?
The SELECT trial specifically studied people with existing cardiovascular disease. While we know GLP-1s improve cardiovascular risk factors like blood pressure and weight in healthy people, large-scale trials showing prevention in those without existing disease are limited.

How long do you need to take GLP-1s to get heart benefits?
Benefits start appearing within 3-6 months, but the medications work best with long-term use. The SELECT trial followed patients for over 3 years.

Will insurance cover GLP-1s for heart health?
Coverage varies. Wegovy has FDA approval for cardiovascular risk reduction, which may improve insurance coverage for those who qualify. Many insurance plans still require prior authorization or don’t cover these medications, making telehealth compounded options attractive.

Can you take GLP-1s if you’re already on heart medications?
Yes. In the SELECT trial, nearly all participants were already on standard cardiovascular medications. GLP-1s provided additional benefit on top of those treatments.

What about side effects?
Common side effects include nausea, vomiting, diarrhea, and constipation. These usually improve over time. Serious side effects are rare but can include pancreatitis and gallbladder problems. Your doctor will monitor you closely.

Do the cardiovascular benefits last after stopping the medication?
Research suggests the benefits are maintained while taking the medication. Some benefit may persist after stopping, but weight regain and loss of metabolic improvements typically occur when treatment is discontinued.

Key Takeaways

✓ Proven Protection: GLP-1 medications reduce heart attack and stroke risk by 20-26% in high-risk individuals

✓ Fast-Acting: Cardiovascular benefits begin within 3-6 months of starting treatment

✓ Beyond Weight Loss: Heart protection occurs through multiple mechanisms independent of weight loss

✓ FDA-Approved: Wegovy is approved specifically to reduce cardiovascular risk in people with obesity and heart disease

✓ Stroke Prevention: Particularly impressive 39% reduction in stroke risk with Ozempic

✓ Works with Standard Care: Provides additional 10-20% risk reduction on top of traditional heart medications

✓ Multiple Options: Both semaglutide and tirzepatide show cardiovascular benefits

The cardiovascular benefits of GLP-1 medications represent a paradigm shift in how we approach heart disease prevention. For people with obesity and cardiovascular disease, these medications offer more than weight loss—they offer life-saving protection.

Your Next Steps

Ready to explore GLP-1 medications for heart health?

Option 1: Traditional Route
Talk to your cardiologist or primary care doctor about whether Ozempic, Wegovy, or Zepbound might be appropriate for your cardiovascular risk profile.

Option 2: Affordable Telehealth Options

Compare Your Options with these provider reviews:

Not sure which option is right for you? Check out our GLP-1 Provider Comparison Guide to see how these services stack up on price, support, and features.

Telehealth Comparrison Guide

Sources

Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice. GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) are prescription medications that may not be suitable for everyone. Cardiovascular disease is a serious medical condition that requires professional medical evaluation and treatment. Always consult with a qualified healthcare provider, preferably a cardiologist or endocrinologist, before starting any new medication or treatment for cardiovascular risk reduction. The information presented here is based on clinical trials and published research but should not replace individualized medical advice. Side effects may include nausea, vomiting, diarrhea, constipation, pancreatitis, gallbladder problems, and in rare cases, more serious complications. This information has not been evaluated by the FDA for the purpose of diagnosing, treating, curing, or preventing cardiovascular disease.

Affiliate Disclaimer

This article contains affiliate links to telehealth GLP-1 providers. If you click through and purchase a service or medication through these links, we may receive a commission at no additional cost to you. These commissions help support our ability to provide free, comprehensive, evidence-based reviews and health information. Our editorial content and recommendations are independent and based on thorough research of clinical trials, FDA approvals, patient reviews, and expert medical guidance. We only recommend services and providers we believe offer genuine value, safety, and quality care to our readers. The decision to use any telehealth service or medication should be made in consultation with your healthcare provider based on your individual medical needs and cardiovascular risk profile.

Updated: May 2026